CN109568538B - Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed - Google Patents
Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed Download PDFInfo
- Publication number
- CN109568538B CN109568538B CN201811139999.2A CN201811139999A CN109568538B CN 109568538 B CN109568538 B CN 109568538B CN 201811139999 A CN201811139999 A CN 201811139999A CN 109568538 B CN109568538 B CN 109568538B
- Authority
- CN
- China
- Prior art keywords
- composition
- silybum marianum
- turmeric
- hangover
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 206010019133 Hangover Diseases 0.000 title claims abstract description 42
- 244000163122 Curcuma domestica Species 0.000 title claims abstract description 35
- 244000272459 Silybum marianum Species 0.000 title claims abstract description 35
- 235000010841 Silybum marianum Nutrition 0.000 title claims abstract description 35
- 244000303040 Glycyrrhiza glabra Species 0.000 title claims abstract description 34
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims abstract description 34
- 235000003373 curcuma longa Nutrition 0.000 title claims abstract description 33
- 235000014552 Cassia tora Nutrition 0.000 title description 10
- 244000201986 Cassia tora Species 0.000 title description 10
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 30
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 30
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 24
- 235000013976 turmeric Nutrition 0.000 claims abstract description 24
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims 5
- 210000000582 semen Anatomy 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 126
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 58
- 230000000694 effects Effects 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000003908 liver function Effects 0.000 abstract description 8
- 210000005229 liver cell Anatomy 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 206010019851 Hepatotoxicity Diseases 0.000 abstract description 3
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 3
- 230000007686 hepatotoxicity Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008513 turmeric extract Substances 0.000 description 3
- 229940052016 turmeric extract Drugs 0.000 description 3
- 235000020240 turmeric extract Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 2
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 238000010932 ethanolysis reaction Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- FPNKCZKRICBAKG-UHFFFAOYSA-N rubrofusarin Chemical compound O1C(C)=CC(=O)C=2C1=CC1=CC(OC)=CC(O)=C1C=2O FPNKCZKRICBAKG-UHFFFAOYSA-N 0.000 description 2
- KLKFLNXANXGSIT-UHFFFAOYSA-N rubrofusarin Natural products O1C(C)=CC(=O)C2=C1C=C1C=C(O)C=C(OC)C1=C2O KLKFLNXANXGSIT-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002445 liver protective agent Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Abstract
The present invention relates to a composition for hangover relief comprising silybum marianum, turmeric, licorice and cassia seed, which has a remarkably excellent effect of decomposing acetaldehyde and ethanol in blood, thereby exhibiting a synergistic effect in hangover relief. In addition, the composition for improving liver function of the present invention is remarkably excellent in the effect of improving liver function by effectively protecting liver cells from hepatotoxicity caused by ethanol.
Description
Technical Field
The present invention relates to a Composition for hangover relief (Composition for human drinking silbum m arianum, cutcuma longa, Glycyrrhiza glabra and Cassia tora) having a remarkably excellent effect of relieving hangover by decomposing acetaldehyde and ethanol in blood.
Background
According to clinical symptoms, alcoholic liver diseases are classified into alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis, and occur when 60 to 80g of alcohol is consumed daily for about 10 years. Alcoholic fatty liver is produced by excessive alcohol intake, and accumulation of cholesterol and neutral fat in liver cells, and can be recovered immediately by giving up alcohol, but if alcohol is continuously drunk, hepatitis will develop. Alcoholic hepatitis is a state in which necrosis and inflammation of liver cells occur, and is manifested by various symptoms such as weakness, loss of appetite, weight loss, jaundice, fever, or right upper abdominal pain. Approximately 40% of alcoholic hepatitis patients will develop alcoholic cirrhosis. Alcoholic cirrhosis, which is impossible to restore to the normal liver state, is manifested by various symptoms such as systemic debilitation, anorexia, ascites, esophageal phlebangioma, hemorrhage, hepatic encephalopathy or coma.
The normal metabolic process of ethanol is that ethanol that flows into the body is absorbed in the gastrointestinal tract or small intestine and moves to the liver through blood vessels. Alcohol Dehydrogenase (ADH) exists in the liver cells, thereby oxidizing ethanol into acetaldehyde, which is decomposed into acetic acid by Acetaldehyde Dehydrogenase (ADH) in the liver cells and transferred to muscles or adipose tissues of the whole body, and finally into carbon dioxide and water. Further, the acetaldehyde dehydrogenase has: type II, which begins to oxidize even if acetaldehyde is at a low concentration, and type I, which does not work if acetaldehyde is not at a high concentration, however, the oriental is often deficient in type II acetalases or deficient in type II acetalases, and thus acetaldehyde is slowly oxidized. Because of the toxic effect of the acetaldehyde and/or ethanol which is not oxidized, the normal metabolism is hindered, and various hangover phenomena are sensed.
Unlike other energy sources, alcohol mostly decomposes in the liver, and alcohol that does not decompose in the liver continues to circulate with the blood and disappears over time. In particular, it is known that the alcohol decomposition efficiency is low because the alcohol decomposition enzyme activity of the easterners such as koreans, chinese, japanese, etc. is low compared to the western ones, and it is a fact that the health problem due to the alcohol not metabolized is serious. In order to solve the problems as described above, a great deal of research is being conducted on drugs or foods capable of detoxifying alcohol and relieving hangover symptoms.
Disclosure of Invention
An object of the present invention is to provide a composition for alleviating hangover, which can significantly suppress the levels of acetaldehyde and ethanol in blood and thereby provide an excellent effect of alleviating hangover.
Another object of the present invention is to provide a composition for improving liver function, which has an excellent effect of restoring liver function by protecting liver cells from hepatotoxicity caused by ethanol.
The present inventors have made intensive studies to develop a composition having an excellent hangover-alleviating effect, and as a result, have confirmed that a combination of a plurality of specific plant extracts exerts a surprising synergistic effect on the inhibition of the levels of acetaldehyde and ethanol in blood, thereby providing a remarkably excellent hangover-alleviating effect, and have completed the present invention.
The present invention provides a composition for hangover relief, which comprises Silybum marianum (Silybum marianum), turmeric (Curcuma longa), licorice (Glycyrrhiza glabra) and Cassia seed (Cassia tora) as active ingredients. The composition containing the combination of the four components as the active ingredient is excellent in the effect of suppressing the levels of acetaldehyde and ethanol in blood. In addition, the composition for hangover relief of the present invention shows an effect remarkably improved, that is, a synergistic effect, compared to the hangover relief effect that each component alone shows.
In the present invention, hangover means symptoms such as headache, diarrhea, anorexia, nausea, vomiting, chills or cold sweat, which are exhibited after drinking. The objective symptoms of hangover include decreased motor ability, blood changes, hormonal changes, and the like. In the present invention, "hangover resolution" may mean that the concentration of acetaldehyde and ethanol in blood is significantly reduced by decomposing or inhibiting them, thereby preventing or resolving hangover symptoms as described above.
In the present invention, it is well known that Silybum marianum (Silybum marianum) is a kind of plants of the compositae family, and a silymarin component extracted from seeds thereof contributes to liver health. Silybum marianum is known to have effective antioxidant effects such as an effect of restoring hepatocytes caused by alcohol or other toxic substances, and preventing new hepatocytes from being damaged by toxins and reducing inflammation, etc.
In the present invention, turmeric (Curcuma longa) contains various useful components in medicinal roots, and the most representative component is Curcumin (Curcumin). It is well known that the main effects of turmeric are to improve liver function and to activate bile secretion.
In the present invention, Glycyrrhiza (Glycyrrhiza glabra) is a plant used as a korean medicinal material, and contains triterpenoid (triterpenoid) saponin, Glycyrrhizin (Glycyrrhiza), liquiritin (liquiritin), asparagine (Asparagin), Glutamic acid (Glutamic acid), glucose, and the like. Glycyrrhizin, which is 2-glucuronic acid (glucuronic) glycoside of glycyrrhizic acid as a sweet component of licorice, has not only a detoxifying effect against drug poisoning, food poisoning or in vivo metabolite poisoning, but also an effect of sterilization and disinfection.
In the present invention, Cassia seed (Cassia tora) is a kind of leguminous plants. It is known that chrysophanol (chrysophanol) and emodin (emodin) contained in cassia seed promote intestinal motility, and cassia obtusin (obtusin) and rubrofusarin (rubrofusarin) have effects of lowering blood pressure and cholesterol values and improving asthenopia.
The composition for hangover relief of the present invention comprises an extract mixture of silybum marianum, turmeric, licorice and cassia seed as active ingredients. In one embodiment of the present invention, each plant extract can be produced by a general method known in the art under general temperature and pressure conditions using a general solvent.
In one embodiment of the present invention, the extract of silybum marianum, turmeric, licorice or cassia seed used in the present invention may be extracted with one or more solvents selected from the group consisting of water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, hexane, benzene, chloroform, glycerin, butylene glycol, propylene glycol and the like.
In one embodiment of the invention, the silybum marianum extract may be extracted from silybum marianum seeds using a multi-solvent (multi solvent). In addition, the turmeric extract may be extracted from the rhizome of turmeric using alcohol. In addition, the cassia seed extract may be extracted from the leaves of cassia seed using water. In addition, the licorice extract may be extracted from the root of licorice using water.
In the hangover relief composition of the present invention, the content of silybum marianum may be 10 to 30% by weight, preferably 15 to 27% by weight, and more preferably 20 to 25% by weight, based on the total weight of the composition. The content of turmeric may be 10 to 30 wt%, preferably 15 to 27 wt%, and more preferably 20 to 25 wt% based on the total weight of the composition. The content of licorice may be 10 to 30 wt%, preferably 12 to 25 wt%, and more preferably 14 to 21 wt% based on the total weight of the composition. In addition, the content of the cassia seed can be 10 to 40 weight percent, preferably 15 to 35 weight percent, and more preferably 20 to 30 weight percent based on the total weight of the composition. When the content of any one of the four components is less than the above content, the decomposition effect of acetaldehyde and ethanol is not sufficiently exerted, and thus the hangover-resolving effect by mixing the components is remarkably reduced. When the content of any one of the four components exceeds the content, the multiplied magnitude of the acetaldehyde and ethanolysis effects is not large, economic efficiency is reduced, and palatability is reduced.
In one embodiment, the weight ratio of silybum marianum, turmeric, licorice and cassia seed in the composition for hangover relief of the present invention may be 1: 0.5-1.5: 0.3-1.5: 0.5 to 1.8 (silybum marianum: turmeric: licorice: cassia seed). Preferably, the weight ratio may be 1: 0.7-1.3: 0.5-1.3: 0.7 to 1.5 (silybum marianum: turmeric: licorice: cassia seed). More preferably, the weight ratio may be 1: 0.8-1.2: 0.7-1.2: 0.8 to 1.3 (silybum marianum: turmeric: licorice: cassia seed). The inventors of the present invention confirmed that the four extracts are mixed at the weight ratio, and the inhibitory effect on acetaldehyde and ethanol in blood is remarkably excellent, thereby producing a synergistic effect on hangover relief.
In one embodiment, the present invention provides a composition for alleviating hangover, comprising, as active ingredients, 100 to 160mg of silybum marianum extract, 100 to 150mg of turmeric extract, 70 to 120mg of licorice extract, and 125 to 175mg of cassia seed extract. The composition may also comprise microcrystalline cellulose as well as silicon dioxide. The composition may be formulated in a capsule form, and the total weight of the ingredients in the capsule form may be 550-600 mg.
The present invention also provides a method for producing a composition for relieving hangover, comprising the step of mixing extracts of Silybum marianum (Silybum marianum), Curcuma longa (Curcuma longa), Glycyrrhiza glabra (Glycyrrhiza glabra), and Cassia tora (Cassia tora). In one embodiment, the extracts can be mixed in the amounts or weight ratios.
The present invention also provides a liver function-improving composition containing Silybum marianum (Silybum marianum), Curcuma longa (Curcuma longa), Glycyrrhiza glabra (Glycyrrhiza glabra), and Cassia seed (Cassia tora) as active ingredients. In the present invention, "improvement of liver function" may mean restoration of liver function and protection of liver cells by the effect of decomposing acetaldehyde and ethanol in blood after liver poisoning by ethanol. In addition, the combination of silybum marianum, turmeric, licorice and cassia seed of the present invention can be used as an active ingredient of health food for hangover relief, a fatigue recovery agent, a liver protective agent or the like.
The ordinary skilled person can determine the dose of the composition for hangover relief of the present invention to be administered at one time according to the absorption degree of the active ingredient, the excretion rate, age and body weight of the subject, sex and state, etc. In one embodiment, the intake amount of the composition for relieving hangover of the present invention is 200 to 3,500mg per adult, and the composition can be taken 2 to 3 times a day. The composition for hangover relief of the present invention can be administered orally or parenterally, and can be administered before and/or after drinking alcohol. The raw materials used in the present invention are safe materials that are allowed to be used as food materials, and their extracts can also be safely ingested within an allowable range.
In order to facilitate oral ingestion, the hangover-alleviating composition of the present invention may further comprise one or more additives selected from pharmaceutically acceptable common diluents, lubricants, binders, disintegrants, sweeteners, stabilizers, nutrients, vitamins, electrolytes, flavors, colorants, pectic acids, alginic acids, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonizing agents, in addition to effective amounts of the respective components. The hangover-alleviating composition of the present invention may be prepared into a general pharmaceutical preparation, such as a liquid, a suspension, a capsule, a tablet, a chewable agent, a pill, or a granule, but is not limited thereto.
Effects of the invention
The composition for alleviating hangover of the present invention significantly decomposes or inhibits acetaldehyde and ethanol in blood, and exhibits synergistic effects in alleviating hangover by combining the four components. In addition, the composition for improving liver function of the present invention can effectively protect against hepatotoxicity caused by ethanol.
Drawings
Fig. 1 is a graph in which the total area under the curve (AUC) showing the experimental result values of the acetaldehyde level in blood of each experimental group is calculated.
Fig. 2 is a graph showing the change in acetaldehyde over time for each experimental group.
Figure 3 is a graph showing the levels of acetaldehyde at various times for each experimental group.
FIG. 4 is a graph showing the experimental result values of the experimental groups (comparative examples 1 to 5) consisting of only one component.
FIG. 5 is a graph showing the experimental result values of the experimental groups (comparative examples 6 to 9) composed of the combination of two components.
FIG. 6 is a graph showing the experimental result values of the experimental groups (comparative examples 10 to 11, and examples 1 to 2) composed of combinations of three or four components.
Fig. 7 is a graph in which the total area under the curve (AUC) showing the experimental result values of the blood ethanol level of each experimental group is calculated.
Fig. 8 is a graph showing the change in ethanol level over time for each experimental group.
Fig. 9 is a graph showing the levels of ethanol at various times for each experimental group.
FIG. 10 is a graph showing the experimental result values of the experimental groups (comparative examples 1 to 5) consisting of only one component.
FIG. 11 is a graph showing the experimental result values of the experimental groups (comparative examples 6 to 9) composed of the combination of two components.
FIG. 12 is a graph showing the experimental result values of the experimental groups (comparative examples 10 to 11, and examples 1 to 2) composed of combinations of three or four components.
Detailed Description
Hereinafter, examples and the like will be described in detail to help understanding of the present invention. However, the embodiments of the present invention may be modified into various other forms, and the scope of the present invention is not to be construed as being limited to the embodiments described below. Embodiments of the present invention are provided to more fully explain the present invention to those skilled in the art.
Experimental example: evaluation of ethanol and acetaldehyde decomposition Effect
(1) Experimental Material
In order to evaluate the effect of various experimental substances during alcohol metabolism associated with hangover, the following experiments were performed. As experimental materials, ethanol (Merck; Item code: 1.00983.0511-500 ML) and acetaldehyde (Source: Sigma; Cat No.: 402788-5 ML) were used.
Male Wistar rats (Albi no Wistar rats, Rattus norvegicus) weighing 245-260 g were used for each group of 8 animals. The experimental animals were adapted to one week of experimental conditions before taking ethanol.
Initial random draws were performed on a recent weight basis. Only animals with individual body weights within ± 20% of the group mean were used. Animals were identified by dilute picric acid solution and caged card. After random drawing, animals were identified by cage card and animal identification.
Rats were divided into four groups during the experiment. The room temperature is kept at 22 +/-3 ℃, and the relative humidity is kept at 30-70%. The artificial light is set to a 12 hour light state and a 12 hour dark state. Rats were provided free uv treated water and laboratory rodent chow obtained from approved enterprises.
(2) Experimental methods
As shown in table 1 below, examples and comparative examples were divided into 13 experimental groups.
[ TABLE 1 ]
The laboratory procedure (Protocol estimate number: IAEC/NR-PCL-03/06/18) was approved by the institute of Animal Ethics (institute of Natural Animal Ethics Co., Inc. (IAEC) of Natural Remedia price Limited, Bangalore) according to the Committee for Animal Experimental Control and Supervision of the laboratory in India (CPCSEA).
The experimental materials of the examples and comparative examples were suspended in 0.5% carboxymethylcellulose (CMC), and the vehicle and experimental materials were orally administered to all animals. After 1 hour of administration of the test substance, 5mL/kg body weight of absolute ethanol was orally administered to the animals. For the determination of ethanol and acetaldehyde, a heparin-treated vial was injected with ethanol and after 30 minutes, 1 hour, 2 hours and 4 hours, blood samples were collected through the retroorbital plexus.
Ethanol (Merck) -100-PPM, 250-PPM, 500-PPM, 1000-PPM &2500-PPM, and acetaldehyde (Sigma) -2-PPM, 5-PPM, 10-PPM, 50-PPM &100-PPM standards were analyzed using an Agilent gas chromatography-headspace flame ionization detector (Head Space with FI D detector). Standards of approximately 1.5mL were made in GC vials and injected using an Agilent 7697A autosampler. Approximately 500. mu.L (. about.500 mg) of heparinized blood was added to a GC vial containing 1mL of 10% perchloric acid. The weight of blood added to each vial was recorded and used in the calculation. Ethanol and acetaldehyde levels were calculated using standards of 500PPM and 10PPM, respectively.
[ TABLE 2 ]
Headspace sampler conditions (conditions)
[ TABLE 3 ]
GC conditions (conditions)
The concentration of ethanol or acetaldehyde was calculated according to the following formula.
The total area under the curve was calculated and the data was processed using the statistical software IBM SPSS version 20. As a multiple comparison (post-hoc) experiment based on the varied amount homogeneity experiment, the bonferoni (B onferroni) test was used. One-way analysis of variance (One way ANOVA) was applied and data are presented by mean ± standard deviation.
(3) Results of the experiment
The levels of ethanol and acetaldehyde in blood were measured using Agilent GC-HS, and the results are shown in the following table.
[ TABLE 4 ]
Effect of test substance on blood acetaldehyde level
(values expressed as Mean ± SEM; n ═ 8, # p <0.05, ethanol control Vs treated group)
The total area under the curve of the experimental result values (AUC) of the acetaldehyde level was calculated and represented graphically in fig. 1. When such results were observed, it was confirmed that the compositions of examples 1 to 2 containing all four components significantly suppressed the level of acetaldehyde in blood as compared with other comparative examples in the same amount.
In addition, the change in acetaldehyde level over time for each experimental group is shown in fig. 2 and 3. The experimental result values of the experimental group consisting of only one component (comparative examples 1 to 5) are shown in fig. 4, the experimental result values of the experimental group consisting of a combination of two components (comparative examples 6 to 9) are shown in fig. 5, and the experimental result values of the experimental group consisting of a combination of three or four components (comparative examples 10 to 11, and examples 1 to 2) are shown in fig. 6.
When the above experimental results were observed, examples 1 to 2 containing four components consisting of cassia seed, silybum marianum, turmeric, and licorice exhibited significantly superior acetaldehyde decomposition or inhibitory effects, compared to the other comparative examples, even though the dose was the same. From these results, it was confirmed that the combination of the four components of the present invention produces synergistic effects on the decomposition or inhibition of acetaldehyde, i.e., the resolution of hangover.
[ TABLE 5 ]
Effect of test substances on blood alcohol levels
(the values are expressed as Mean + -SEM; n-8)
The total area under the curve of the experimental result values (AUC) for the ethanol levels was calculated and is graphically represented in fig. 7. When such results were observed, it was confirmed that the compositions of examples 1 to 2 containing all four components significantly suppressed the ethanol level in blood, as compared with the other comparative examples in the same amount.
In addition, the change in ethanol level with time for each experimental group is shown in fig. 8 and 9. The experimental result values of the experimental groups consisting of only one component (comparative examples 1 to 5) are shown in FIG. 10, the experimental result values of the experimental groups consisting of a combination of two components (comparative examples 6 to 9) are shown in FIG. 11, and the experimental result values of the experimental groups consisting of a combination of three or four components (comparative examples 10 to 11, and examples 1 to 2) are shown in FIG. 12.
When the experimental results were observed, examples 1 to 2 including four components consisting of cassia seed, silybum marianum, turmeric, and licorice exhibited significantly superior ethanolysis or inhibitory effects, compared to the other comparative examples, even though the dose was the same. From these results, it was confirmed that the combination of the four components of the present invention produces a synergistic effect on ethanol decomposition or inhibition, i.e., hangover relief.
Preparation example: preparation of hangover-relieving composition
In order to produce a composition for hangover relief, silybum marianum, turmeric, licorice and cassia seed as active ingredients were prepared by the following methods, respectively.
Extracting and filtering Cassia tora leaves (Cassia tora leaves) with water at 90-95 deg.C, washing the filtrate, and concentrating with 25-30% T.S at NMT70 deg.C under 550mmHg vacuum. Thereafter, spray-drying was carried Out at an inlet (Inlet) temperature of 160 ℃ to 175 ℃ and an outlet (Outlet) temperature of 105 ℃ to 115 ℃, and then, the resultant was pulverized and sieved (sieve). Licorice root (Glycyrrhiza glabra roots) is also extracted by the same method as the cassia seed leaves.
Extracting and filtering Curcuma rhizome (Curcuma longa rhizome) with 75-80 deg.C ethanol, washing the filtrate, and concentrating with 50-60% T.S at NMT70 deg.C under 450-550mmHg vacuum. Thereafter, a cloudy cream formulation was made by vacuum drying at NMT80 ℃.
The Silybum marianum seeds (Silybum marianum seeds) are extracted by ethyl acetate, then vacuum-concentrated, dissolved in ethanol at 70-75 ℃ and filtered. After washing the filtrate, the filtrate was concentrated by 50-60% T.S at NMT70 ℃ under vacuum of 450-550 mmHg. Thereafter, after vacuum drying at NM T80 ℃, the extract was produced by crushing and sieving.
According to a general capsule preparation method, 130mg of silybum marianum extract, 125mg of turmeric extract, 95mg of licorice extract, 150mg of cassia seed extract, microcrystalline cellulose and silicon dioxide were mixed and filled into a gelatin capsule, thereby preparing a capsule.
[ TABLE 6 ]
Claims (2)
1. A composition for relieving hangover is provided, wherein,
the effective components are silybum marianum, turmeric, liquorice and cassia seed,
the content of the silybum marianum is 10-30 wt% relative to the total weight of the composition,
the content of the turmeric is 10-30 wt% relative to the total weight of the composition,
the content of the liquorice is 10 to 30 percent by weight relative to the total weight of the composition,
the content of the cassia seed is 10-40 wt% relative to the total weight of the composition,
the weight ratio of the silybum marianum, the turmeric, the liquorice and the cassia seed is as follows: turmeric: licorice root: the cassia seed is counted as 1: 0.5-1.5: 0.3-1.5: 0.5 to 1.8.
2. A method for producing a composition for hangover relief, wherein,
comprises the steps of mixing extracts of silybum marianum, turmeric, licorice and cassia seeds,
the composition for relieving hangover comprises effective components of herba Silybi Mariani, Curcuma rhizome, Glycyrrhrizae radix and semen Cassiae,
the content of the silybum marianum is 10-30 wt% relative to the total weight of the composition,
the content of the turmeric is 10-30 wt% relative to the total weight of the composition,
the content of the liquorice is 10 to 30 percent by weight relative to the total weight of the composition,
the content of the cassia seed is 10-40 wt% relative to the total weight of the composition,
the weight ratio of the silybum marianum, the turmeric, the liquorice and the cassia seed is as follows: turmeric: licorice root: the cassia seed is counted as 1: 0.5-1.5: 0.3-1.5: 0.5 to 1.8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126990 | 2017-09-29 | ||
| KR10-2017-0126990 | 2017-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109568538A CN109568538A (en) | 2019-04-05 |
| CN109568538B true CN109568538B (en) | 2022-02-25 |
Family
ID=65919977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811139999.2A Active CN109568538B (en) | 2017-09-29 | 2018-09-28 | Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed |
Country Status (2)
| Country | Link |
|---|---|
| KR (2) | KR20190038386A (en) |
| CN (1) | CN109568538B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220115220A (en) | 2021-02-10 | 2022-08-17 | 주식회사 우진생활건강 | Composition containing calamansi for relieving hang-over |
| KR102642547B1 (en) * | 2022-11-11 | 2024-03-05 | 한국식품연구원 | Composition for improving relieving hangover and liver function comprising the Levilactobacillus brevis WiKim0168 |
| KR102642548B1 (en) * | 2022-11-11 | 2024-03-05 | 한국식품연구원 | Composition for improving relieving hangover and liver function comprising the Pediococcus acidilactici WiKim0170 |
| CN117338860A (en) * | 2023-11-13 | 2024-01-05 | 吴剑波 | Preparation method of extract for promoting glycolysis and application of extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336193A (en) * | 2000-07-31 | 2002-02-20 | 雷学军 | Antilipenic functional water containing natural medicine component and its compounding process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100638491B1 (en) * | 2004-05-18 | 2006-10-25 | 약초나라(주) | Compounds for relief of alcoholic hangover and drug containing the compounds |
| KR101301094B1 (en) | 2011-05-02 | 2013-08-28 | 보해양조주식회사 | Composition for relieving hangover or improving liver function |
| KR20130092652A (en) * | 2012-02-12 | 2013-08-21 | 왕연중 | Natural tea having an effect on the hangover |
-
2018
- 2018-09-27 KR KR1020180114953A patent/KR20190038386A/en active Application Filing
- 2018-09-28 CN CN201811139999.2A patent/CN109568538B/en active Active
-
2019
- 2019-05-09 KR KR1020190054541A patent/KR102083661B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336193A (en) * | 2000-07-31 | 2002-02-20 | 雷学军 | Antilipenic functional water containing natural medicine component and its compounding process |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190051938A (en) | 2019-05-15 |
| CN109568538A (en) | 2019-04-05 |
| KR20190038386A (en) | 2019-04-08 |
| KR102083661B1 (en) | 2020-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109568538B (en) | Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed | |
| Ruzaidi et al. | The effect of Malaysian cocoa extract on glucose levels and lipid profiles in diabetic rats | |
| KR101601080B1 (en) | Composition comprising curcuma longa extract together with curcuma zedoaria extract | |
| CN101365465A (en) | Composition comprising liquiritigenin for preventing and treating liver disease | |
| KR102001740B1 (en) | Liquid composition for preventing and relieving hangover with high content of ginsenoside F2, R3 and compound K comprising and preparation method thereof | |
| JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
| KR20110128385A (en) | The herb medicine composition material and the manufacturing process for pimple skin-improvement uses by midam cheonggyeolan | |
| JP2005350453A (en) | Slightly water-soluble component of leaf of lagerstroemia speciosa l. | |
| Feyisayo et al. | Anti-hyperglycaemic, anti-inflammatory and anti-oxidant activities of Carica papaya and Citrullus lanatus seeds | |
| JP4693964B2 (en) | New antifeedant | |
| CN115177558B (en) | Antibacterial explosion bead of tree peony root bark extract and preparation method and application thereof | |
| KR20200036715A (en) | Composition for improving fatigue recovery or exercise performance comprising angelica gigas nakai extract, cnidium officinale makino extract and paeonia japonica extract | |
| JP3549997B2 (en) | Food composition and pharmaceutical composition having lipase inhibitory effect | |
| CN107348491A (en) | Prevent liver diseases drink and preparation method thereof | |
| Saddam | Effect of chicory (cichorium intybus l.) Leaves extract to protect certain liver enzymes in mice against carbon tetrachloride-induced hepatotoxicity | |
| KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
| Abd El-Ghany et al. | Anti-diabetic effect of some herbs and fruit against streptozotocin induced diabetic rats | |
| KR20060106065A (en) | Hepato-protective effects of angelica keiskei root extract, 4-hydroxyderricin and xanthoangelol | |
| KR20190125735A (en) | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract | |
| KR20200016610A (en) | Composition for Improvement of Fatty Liver | |
| JP2955679B2 (en) | Ethanol metabolism promoter | |
| KR100977583B1 (en) | Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same | |
| JP4673474B2 (en) | New liver disorder inhibitor | |
| KR20080109116A (en) | Beverage for relieving hangover and manufacturing method thereof | |
| JP4712928B2 (en) | Chronic hepatitis inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |